Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Next Previous
Search
Trial Profile

A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inebilizumab (Primary)
  • Indications Neuromyelitis optica
  • Focus Registrational; Therapeutic Use
  • Acronyms N-MOmentum
  • Sponsors AstraZeneca; MedImmune

    • Most Recent Events

    • 01 Jun 2024 Results (data cutoff Dec 18, 2020, n=225) assessing Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder published in the Lancet Neurology
    • 18 Apr 2024 Results (n=211) assessing the relationship between cytokine levels and disease activity in Neuromyelitis Optica Spectrum Disorder presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 18 Apr 2024 Results evaluating the long-term comparative efficacy of inebilizumab (INEB) over N-MOmentum open label period, presented at the 76th Annual Meeting of the American Academy of Neurology 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top